Abstract
Congenital cytomegalovirus (CMV) infection is potentially devastating. Although nonrandomized studies have suggested benefit from hyperimmune globulin administered to pregnant women with primary CMV infection, no randomized trials had been done for verification. Now, researchers in Italy have conducted a phase II, double-blind, multicenter study to evaluate the efficacy of this agent. Pregnant women with primary infection at 5 to 26 weeks of gestation and presumed onset …
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call